Efficacy and safety of neoadjuvant double anti-Her2 blockade combined with anthracycline-free chemotherapy in locally advanced breast cancer

被引：0
|
作者：
Rodriguez Garces, Maria Yeray
Garcia Samblas, Victoria
Morales Pancorbo, David
Bayo Calero, Juan Lucas
机构：
[1] Hosp Juan Ramon Jimenez, Huelva, Spain
[2] Juan Ramon Jimenez Hosp, Huelva, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e12612
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: Efficacy analysis of a phase II cardiac safety study (TRYPHAENA)
    Schneeweiss, A.
    Chia, S.
    Hickish, T.
    Harvey, V.
    Eniu, A.
    Waldron-Lynch, M.
    Eng-Wong, J.
    Kirk, S.
    Cortes, J.
    CANCER RESEARCH, 2017, 77
  • [22] Efficacy, cardiotoxicity and factors affecting pathologic complete response of neoadjuvant chemotherapy with anthracycline-containing verses anthracycline-free regimens plus dual HER2 blockade for HER2-positive early-stage breast cancer: a retrospective study
    Lu, Hang
    Yan, Han
    Liao, Shichong
    Deng, Jingwen
    Zhang, Jiucheng
    Yao, Feng
    Zheng, Hongmei
    Sun, Shengrong
    Zhang, Yimin
    TRANSLATIONAL CANCER RESEARCH, 2023, 12 (06) : 1490 - 1502
  • [23] Nine-Year Median Follow-up of Cardiotoxicity and Efficacy of Trastuzumab Concurrently With Anthracycline-Based and Anthracycline-Free Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer Patients
    He, Xuexin
    Dai, Xiaolan
    Ji, Jiali
    Liu, Hong
    Shi, Ganggang
    Yeung, Sai-Ching Jim
    CLINICAL BREAST CANCER, 2022, 22 (01) : E80 - E90
  • [24] The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients
    Stamatovic, Ljiljana
    Susnjar, Snezana
    Gavrilovic, Dusica
    Minic, Ivana
    Ursulovic, Tamara
    Dzodic, Radan
    JOURNAL OF BUON, 2018, 23 (05): : 1273 - 1280
  • [25] Comparative efficacy of anthracycline-free and anthracycline-containing neoadjuvant chemoimmunotherapy regimens for triple-negative breast cancer
    Wei, Yuhan
    Li, Qiao
    Mo, Hongnan
    Qi, Yalong
    Ge, Hewei
    Sun, Xiaoying
    Fan, Ying
    Zhang, Pin
    Wang, Jiayu
    Luo, Yang
    Wang, Jing
    Ma, Fei
    TRANSLATIONAL ONCOLOGY, 2025, 51
  • [26] The influence of breast cancer subtypes on response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients
    Susnjar, S.
    Stamatovic, L.
    Gavrilovic, D.
    Minic, I.
    Ursulovic, T.
    BREAST, 2017, 32 : S81 - S82
  • [27] Efficacy and safety of anti-HER2 therapy in neoadjuvant therapy for HER2positive breast cancer: a network meta-analysis
    Gan, Lu
    Li, Fangxuan
    Su, Jialin
    CANCER RESEARCH, 2024, 84 (09)
  • [28] Clinical and pathological predictors of the response to neoadjuvant anthracycline chemotherapy in locally advanced breast cancer
    Fernández-Sánchez, M
    Gamboa-Dominguez, A
    Uribe, N
    García-Ulloa, AC
    Flores-Estrada, D
    Candelaria, M
    Arrieta, O
    MEDICAL ONCOLOGY, 2006, 23 (02) : 171 - 183
  • [29] Taxane and Anthracycline Based Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer : Institutional Experience
    Gogia, Ajay
    Raina, Vinod
    Deo, Suryanarayan Vishnu
    Shukla, Nootan Kumar
    Mohanti, Bidhu Kalyan
    Sharma, Daya Nand
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (05) : 1989 - 1992
  • [30] Clinical and pathological predictors of the response to neoadjuvant anthracycline chemotherapy in locally advanced breast cancer
    Mónica Fernández-Sánchez
    Armando Gamboa-Dominguez
    Norma Uribe
    Ana Cristina García-Ulloa
    Diana Flores-Estrada
    Myrna Candelaria
    Oscar Arrieta
    Medical Oncology, 2006, 23 : 171 - 183
12345